These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.
Novo Nordisk’s Ozempic, Wegovy, and Rybelsus are all part of the same category of drugs called semaglutides, which originally were developed to treat type 2 diabetes—in part by helping people shed pounds better than any previous medication and therefore control their blood sugar. But it wasn’t until recently that their weight-loss feature propelled them to be among the most in-demand prescription medications. Still, the drugs aren’t without controversy over inappropriate use and side effects, including stomach and intestinal issues, that have prompted a warning from the FDA.
More Must-Reads from TIME
- The 100 Most Influential People in AI 2024
- Inside the Rise of Bitcoin-Powered Pools and Bathhouses
- How Nayib Bukele’s ‘Iron Fist’ Has Transformed El Salvador
- What Makes a Friendship Last Forever?
- Long COVID Looks Different in Kids
- Your Questions About Early Voting, Answered
- Column: Your Cynicism Isn’t Helping Anybody
- The 32 Most Anticipated Books of Fall 2024
